慢性心力衰竭(CHF)的治疗目标不仅仅是改善症状、提高生活质量,更重要的是延缓和防止心室重构发展,降低CHF死亡率和住院率,目前临床药物治疗仍居主导地位。血管紧张素转化酶抑制剂(ACEI)一直是CHF治疗的一线药物,血管紧张素Ⅱ受体阻断剂(ARB)对CHF预后也有益,但与ACEI相比,其并无显著优势。本文综述ACEI在CHF治疗中的临床地位。 The goal of treatment for chronic heart failure (CHF) is not only to improve the symptoms and improve the quality of life, but more importantly, to delay and prevent the development of ventricular remodeling and reduce the mortality and hospitalization rate of CHF. At present, clinical drug therapy still dominates. Angiotensin converting enzyme inhibitors (ACEIs) have been first-line drugs for CHF and angiotensin II receptor blockers (ARBs) are also beneficial in CHF prognosis, but have no significant advantage over ACEIs. This article reviews the clinical status of ACEI in the treatment of CHF.